~~<i id='FAFDF3663A'><strike id='FAFDF3663A'><tt id='FAFDF3663A'><pre id='FAFDF3663A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

explore

entertainment

author：entertainment 2025-09-14 21:56:40 - browse：282

Aduhelm, a pioneering treatment for Alzheimer’s disease that collapsed under corporate mistakes and regulatory controversy, is now a cautionary tale in pharmaceutical history.

This week Biogen said it would no longer sell or study the medicine, which first won approval in 2021, ending an era for one of biotech’s storied companies and leaving the rest of the industry to piece together the lessons of a would-be blockbuster that never took off.

STAT reporters took a stab at the Aduhelm legacy — for biotech, Biogen, and Alzheimer’s research — on a recent episode of the Readout LOUD. Here’s an edited transcript of that conversation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： HPV cancer vaccine study demonstrates efficacy

entertainment

hotspot

explore

leisure time

explore

knowledge

Underamicroscope,humanprostatecancercells,colorizedinblue,appearinanairbubble.AdobeAnearly-stageclin

WSS

Protect nursing home residents from future pandemics

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

The world needs the new pandemic treaty

Achieving telehealth equity for people with hearing loss

Extreme heat events are a public health emergency

Guardant Health colon cancer test endorsed by FDA advisory panel

explore

entertainment

entertainment

At least 13 dead in Texas as scorching temps continue

Stroke rates rising, especially in working

Sports medicine is finally prioritizing gender equality

Diversify hospital leadership teams to protect BIPOC patient health

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

Cancer drug shortages should be causing more outrage

Stroke rates rising, especially in working

Medical leaders decry Supreme Court decision on affirmative action

A clever new way to fix Medicaid and graduate medical education

hotspot

Achieving telehealth equity for people with hearing loss

Stroke rates rising, especially in working

Will General Catalyst be the first of many hospital takeovers?

FDA approves Recor Medical high blood pressure device

MoonLake credibility takes another hit with mid

Why some fertility treatments produce more boy babies

explore

leisure time

explore

knowledge